Barclays lowered the firm’s price target on Chemours (CC) to $16 from $19 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for the chemicals and packaging group. The firm made negative commodity revisions and is “patiently waiting” for a turn. The overhangs on cyclical names are likely not to be addressed this quarter, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC:
- Chemours Company: Undervalued Growth Potential Driven by TSS Segment and Market Opportunities
- Chemours upgraded to Outperform from Neutral at Mizuho
- Chemours and Energy Fuels partner to expand domestic mineral supply chain
- Energy Fuels, Chemours form rare earth and critical mineral supply chain pact
- Chemours, NTT Data, Hibiya Engineering partner on Opteon 2P50 trial